CLINUVEL PHARMACEUTICALS earnings per share and revenue

UR9 earnings per share for the last semiannual are 0.13 EUR whereas the estimation was 0.16 EUR which accounts for -17.65% surprise. Företagets omsättning för samma period uppgår till 19.90 M EUR trots den uppskattade siffran 21.46 M EUR. Estimated earnings per share for the next semiannual are 0.30 EUR, and revenue is expected to reach 35.04 M EUR. Also watch annual changes over time to get a bigger picture of UR9 earnings per share and revenue dynamics.